(21 days)
Not Found
No
The summary describes a dental implant system and its components, focusing on mechanical properties and surgical procedures. There is no mention of AI or ML technology.
Yes
This device is a dental implant system used for restorative purposes in dentistry, which falls under the definition of a therapeutic device designed to treat or alleviate a medical condition.
No
This device is a dental implant system used for restorative procedures (implants, crowns, bridges, overdentures), not for diagnosing medical conditions.
No
The device description explicitly states that the system consists of physical components including dental implants, surgical and laboratory instruments, and prosthetic components. This indicates it is a hardware-based medical device, not software-only.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Description: The XiVE® TG Dental Implant System is described as a system of dental implants, surgical and laboratory instruments, and prosthetic components. These are physical devices implanted into the body or used in surgical procedures.
- Intended Use: The intended use is for the surgical placement of dental implants to support crowns, bridges, and overdentures. This is a surgical and restorative procedure, not a diagnostic test performed on a sample.
The device is clearly a medical device used for surgical and prosthetic purposes within the body, not for analyzing samples outside the body for diagnostic purposes.
N/A
Intended Use / Indications for Use
The XiVE® TG Dental Implant System is indicated for singlestage implant placement, with a minimum healing phase of three months in good quality bone and four months in spongy bone, for maxillary and mandibular spinted crowns, bridges and bar-retained overdenture restorations. The bridge must be supported by a minimum of two transgingival threaded implants.
In the edentulous maxilla, a minimu of four transgingival implants are placed in a trapezoidal distribution and rigidly splinted together.
In the edentulous mandible, a minimum of four transgingival implants (> 9.5mm length) are placed between the mental foramina and rigidly splinted together. In this case, bar prosthetic loading is possible immediately after implant placement.
Product codes
DZE
Device Description
The XiVE® TG Dental Implant System consists of transgingival threaded dental implants in 3.4 -4.5mm diameters with 8 - 18mm lengths. The implants are coated with the FRIADENT Surface M2.1. The XiVE® TG Dental Implant System is comprised of dental implants, surgical and laboratory instruments and prosthetic components. The system is designed for single stage procedures for splinted crowns, bridges and complete dentures. In the edentulous mandible, the XiVE® TG transgingival dental implants are indicated for immediate loading procedures using the standard protocol.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
maxillary and mandibular, edentulous maxilla, edentulous mandible, between the mental foramina
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Performance evaluations of the XiVE® TG dental implant system show that the device performs as intended.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 872.3640 Endosseous dental implant.
(a)
Identification. An endosseous dental implant is a prescription device made of a material such as titanium or titanium alloy that is intended to be surgically placed in the bone of the upper or lower jaw arches to provide support for prosthetic devices, such as artificial teeth, in order to restore a patient's chewing function.(b)
Classification. (1) Class II (special controls). The device is classified as class II if it is a root-form endosseous dental implant. The root-form endosseous dental implant is characterized by four geometrically distinct types: Basket, screw, solid cylinder, and hollow cylinder. The guidance document entitled “Class II Special Controls Guidance Document: Root-Form Endosseous Dental Implants and Endosseous Dental Implant Abutments” will serve as the special control. (See § 872.1(e) for the availability of this guidance document.)(2)
Classification. Class II (special controls). The device is classified as class II if it is a blade-form endosseous dental implant. The special controls for this device are:(i) The design characteristics of the device must ensure that the geometry and material composition are consistent with the intended use;
(ii) Mechanical performance (fatigue) testing under simulated physiological conditions to demonstrate maximum load (endurance limit) when the device is subjected to compressive and shear loads;
(iii) Corrosion testing under simulated physiological conditions to demonstrate corrosion potential of each metal or alloy, couple potential for an assembled dissimilar metal implant system, and corrosion rate for an assembled dissimilar metal implant system;
(iv) The device must be demonstrated to be biocompatible;
(v) Sterility testing must demonstrate the sterility of the device;
(vi) Performance testing to evaluate the compatibility of the device in a magnetic resonance (MR) environment;
(vii) Labeling must include a clear description of the technological features, how the device should be used in patients, detailed surgical protocol and restoration procedures, relevant precautions and warnings based on the clinical use of the device, and qualifications and training requirements for device users including technicians and clinicians;
(viii) Patient labeling must contain a description of how the device works, how the device is placed, how the patient needs to care for the implant, possible adverse events and how to report any complications; and
(ix) Documented clinical experience must demonstrate safe and effective use and capture any adverse events observed during clinical use.
0
SECTION 17: SUMMARY OF SAFETY AND EFFECTIVENESS
This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and CFR 807.92.
SUBMITTER INFORMATION 17.1
| a. Company Name: | FRIADENT GmbH. |
|---|---|
| b. Company Address: | Steinzeugstrasse 50 |
| Mannheim D-68229 | |
| Germany | |
| c. Company Phone: | |
| Company Facsimile: | (011) 49 621 43 02 1121 |
| (011) 49 621 43 02 2121 | |
| d. Contact Person: | Heike Dietzler |
| Regulatory Affairs Manager | |
| e. Date Summary Prepared: | July 22, 2003 |
DEVICE IDENTIFICATION 17.2.
| a. Trade/Proprietary Name: | XiVE® TG Dental Implant System |
|---|---|
| b. Classification Name: | Endosseous Dental Implants |
| 21 CFR 872.3640 |
IDENTIFICATION OF PREDICATE DEVICES 173
| Company | Device | 510(k) No. | Date Cleared |
|---|---|---|---|
| FRIADENT GmbH | XIVE® Transgingival | ||
| Dental Implant System | K024004 | 03/03/2003 |
1
DEVICE DESCRIPTION 17.4
The XiVE® TG Dental Implant System consists of transgingival threaded dental implants in 3.4 -4.5mm diameters with 8 - 18mm lengths. The implants are coated with the FRIADENT Surface M2.1. The XiVE® TG Dental Implant System is comprised of dental implants, surgical and laboratory instruments and prosthetic components. The system is designed for single stage procedures for splinted crowns, bridges and complete dentures. In the edentulous mandible, the XiVE® TG transgingival dental implants are indicated for immediate loading procedures using the standard protocol.
SUBSTANTIAL EQUIVALENCE 17.5
The XiVE® TG transgingiyal dental implants with the FRIADENT Surface M2.1 are substantially equivalent to the current XiVE® TG Dental Implant Systems in terms of design, materials, mechanical strength, prosthetic and laboratory options and intended use. The purpose of this submission is to apply the new FRIADENT Surface M2.1 to the endosseous implants.
INTENDED USE 17.6
The XiVE® TG Dental Implant System is indicated for single-stage implant placement, with a minimum healing phase of three months in good quality bone and four months in spongy bone, for maxillary and mandibular splinted crowns, bridges and bar-retained overdenture restorations. The bridge must be supported by a minimum of two transgingival threaded implants. In the edentulous maxilla, a minimum of four transgingival implants are placed in a trapezoidal distribution and rigidly splinted together. In the edentuolous mandible, a minimum of four XiVE® TG transgingival dental implants (≥9.5mm length) are placed between the mental foramina and rigidly splinted together. In this case, bar prosthetic loading is possible immediately after implant placement.
2
TECHNOLOGICAL CHARACTERISTICS 17.7
The XiVE® TG transgingival dental implant is available in 3.4, 3.8, and 4.5mm screw-type implants with the FRIADENT Surface M2.1. The lengths of the implants range from 8 - 18mm. The XiVE® TG transgingival dental implants are constructed of CP-2 titanium. A variety of prosthetic options are available for the XiVE® TG system including, AuroBase, PassivFit, Gold Copings, Ball and Socket Attachments, Bar / Clip, and Select Abutments.
The XiVE® TG transgingival dental implants with the FRIADENT Surface M2.1 is equivalent to the current XiVE® TG Dental Implant System in terms of design, materials, mechanical strength, prosthetic options, instructions for use and intended use. The only difference is the change in the surface morphology of the dental implant to the FRIADENT Surface M2.1.
17.8 CLASS III CERTIFICATION AND SUMMARY
This notification contains a Class III certification and summary of adverse safety and effectiveness information pursuant to 513(f) of the Federal Food, Drug, and Cosmetic Act.
CONCLUSIONS 17.9
This notification contains all information required by 21 CFR 807.87. A completed copy of the Premarket Notification 510(k) Reviewer's Checklist is provided in this submission. Performance evaluations of the XiVE® TG dental implant system show that the device performs as intended. Comparison of the XiVE® TG dental implant system to the predicate devices show that the device is substantially equivalent. The complete surface characterization of the new FRIADENT Surface M2.1 has been detailed in a Device Master File.
3
Image /page/3/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract design featuring a stylized eagle or bird-like figure with flowing lines, representing the department's mission related to health and human well-being. The image is in black and white.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
AUG 1 4 2003
FRIADENT GmbH C/O Ms. Carol Patterson Patterson Consulting Group, Incorporated 21911 Erie Lane Lake Forest, California 92630
Re: K032284
Trade/Device Name: XiVE® TG Dental Implant System Regulation Number: 872.3640 Regulation Name: Endosseous Implant Regulatory Class: III Product Code: DZE Dated: July 22, 2003 Received: July 24, 2003
Dear Ms. Patterson:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
4
Page 2 - Ms. Patterson
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21
CFR Part 807): labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If vou desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4613. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html
Sincerely vours.
Susan Runge
Susan Runner, DDS, MA Interim Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
5
K03284
INDICATION FOR USE
510(k) Number:
Device Name:
XiVE® TG Dental Implant System
Indications for Use:
The XiVE® TG Dental Implant System is indicated for singlestage implant placement, with a minimum healing phase of three months in good quality bone and four months in spongy bone, for maxillary and mandibular spinted crowns, bridges and bar-retained overdenture restorations. The bridge must be supported by a minimum of two transgingival threaded implants.
In the edentulous maxilla, a minimu of four transgingival implants are placed in a trapezoidal distribution and rigidly splinted together.
In the edentulous mandible, a minimum of four transgingival implants (> 9.5mm length) are placed between the mental foramina and rigidly splinted together. In this case, bar prosthetic loading is possible immediately after implant placement.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Kei Mulvey for MSR | |
|---|---|
| (Division Sign-Off) |
Division of Anesthesiology, General Hospital,
Infection Control, Dental Devices
| 510(k) Number: | K 032284 |
|---|---|
| Prescription Use | X |
| OR | |
| Over-The-Counter Use |
(Per 21 CFR 801.109)CONFIDENTIAL